← Back to Clinical Trials
Recruiting NCT06434012

NCT06434012 Barts Endocarditis Research Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06434012
Status Recruiting
Phase
Sponsor Queen Mary University of London
Condition Infective Endocarditis
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2019-04-24
Primary Completion 2029-04-24

Eligibility & Interventions

Sex All sexes
Min Age 16 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
registry

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2019-04-24 with a primary completion date of 2029-04-24.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The Barts Endocarditis Research Registry is being set up to give a unique opportunity to assess the characteristics of Infective Endocarditis (IE) in our population cohort, the current use of imaging techniques, as well as the implementation of the ESC guidelines and its consequence in terms of prognosis. All this will help improve the diagnosis and management of IE. The registry will also form the core of all our subsequent work, including interventional studies. The endocarditis research registry is to record the epidemiological, demographic, microbiological, surgical and outcome data in our cohort of endocarditis patients. This work will underpin all future work in endocarditis by clearly defining our patient cohort and the outcomes from treatment. We have a series of studies planned that we believe will influence the management of endocarditis (we are working up proposals for genomic and therapeutic trials that will subsequently be presented for ethical and hospital approval). The registry will be generic to all our planned studies, and will allow us to capture data to assess treatment effectiveness

Eligibility Criteria

Inclusion Criteria: * • Patients aged 16 and over (Patients under 16 years of age are not admitted to Barts Heart Centre) * Patients admitted to Barts Heart Centre with confirmed Endocarditis (see above) * Patients attending outpatients with confirmed/suspected Endocarditis * Patients with possible IE who complete treatment for endocarditis * Patients with cardiac device related Endocarditis * Patients with the ability to provide informed consent Exclusion Criteria: * • Patients with pacemaker pocket infection with no evidence of pacemaker lead or valve infection * Patients who refuse consent to be included in the research database * Patients with "rejected" endocarditis

Contact & Investigator

Central Contact

Innocent Bvekerwa, MSc

✉ i.bvekerwa@nhs.net

📞 07852209005

Principal Investigator

Simon Woldman, MSc

PRINCIPAL INVESTIGATOR

St Bartholomews Hospital

Frequently Asked Questions

Who can join the NCT06434012 clinical trial?

This trial is open to participants of all sexes, aged 16 Years or older, studying Infective Endocarditis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06434012 currently recruiting?

Yes, NCT06434012 is actively recruiting participants. Contact the research team at i.bvekerwa@nhs.net for enrollment information.

Where is the NCT06434012 trial being conducted?

This trial is being conducted at London, United Kingdom.

Who is sponsoring the NCT06434012 clinical trial?

NCT06434012 is sponsored by Queen Mary University of London. The principal investigator is Simon Woldman, MSc at St Bartholomews Hospital. The trial plans to enroll 1,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology